europe < european < europeans

Facettes : Author.f AffPays.f AffOrg.f AffRegion.f AffVille.f

List of bibliographic references

Number of relevant bibliographic references: 28.
[0-20] [0 - 20][0 - 28][20-27][20-40]

Ident.	Authors (with country if any)	Title
000068 (2012)	Yee Chiu [Royaume-Uni] ; Andrew J. K. Ostor [Royaume-Uni] ; Anthony Hammond [Royaume-Uni] ; Katharina Sokoll [Royaume-Uni] ; Marina Anderson [Royaume-Uni] ; Maya Buch [Royaume-Uni] ; Michael R. Ehrenstein [Royaume-Uni] ; Patrick Gordon [Royaume-Uni] ; Sophia Steer [Royaume-Uni] ; Ian N. Bruce [Royaume-Uni]	Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales
000087 (2011)	K. Krüger [Allemagne] ; B. Hellmich [Allemagne] ; A. Rubbert-Roth [Allemagne] ; U. Müller-Ladner [Allemagne] ; A. Kielhorn [Allemagne]	Ist der Vergleich verschiedener Studien zur Wirksamkeit von Biologika bei Patienten mit rheumatoider Arthritis möglich?
000099 (2010)	Chi Chiu Mok [Hong Kong] ; Lai Shan Tam [Hong Kong] ; Tak Hin Chan [Hong Kong] ; Gavin K. W. Lee [Hong Kong] ; Edmund K. M. Li [Hong Kong]	Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology
000166 (2013)	J. Wollenhaupt [Allemagne] ; K. Albrecht [Allemagne] ; K. Krüger [Allemagne] ; U. Müller-Ladner [Allemagne]	The new 2012 German recommendations for treating rheumatoid arthritis
000194 (2007)	M. Schneider [Allemagne]	Exploring new territory: considering the future
000236 (2016)	Katsuhisa Masaki [Japon]	The 31st European Committee for Treatment and Research in Multiple Sclerosis
000462 (2013)	Reinhard P. T. Rychlik [Allemagne]	Target patient population: how does the regulatory and reimbursement view differ? Insights from the German IQWiG
000466 (2009)	Taio Naniwa [Japon] ; Maiko Watanabe [Japon] ; Shogo Banno [Japon] ; Tomoyo Maeda [Japon]	Adding low dose tacrolimus in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies
000519 (2010)	Steven Simoens [Belgique] ; Thomas De Rijdt [Belgique] ; Paul Declerck	Monoclonal antibodies: indications, budget impact and use
000681 (2008)	Rhonda Siddall	An overview of the clinical trial data presented at the 44th American Society of Clinical Oncology Annual Meeting (ASCO) and the 9th Annual European Congress of Rheumatology (EULAR)
000699 (2012)	Young Ho Lee [Corée du Sud] ; Sang-Cheol Bae [Corée du Sud] ; Sung Jae Choi [Corée du Sud] ; Jong Dae Ji [Corée du Sud] ; Gwan Gyu Song [Corée du Sud]	The association between interleukin-6 polymorphisms and rheumatoid arthritis: a meta-analysis
000727 (2013)	G. Burmester [Allemagne] ; T. Takeuchi [Japon] ; O. Barbarash [Russie] ; G. Ranganna [Royaume-Uni] ; D. Close [Royaume-Uni] ; A. Godwood [Royaume-Uni] ; D. Saurigny [Royaume-Uni]	FRI0232 Consistent efficacy and safety outcomes between european and japanese subjects with rheumatoid arthritis following treatment with mavrilimumab in the phase 2 earth study
000779 (2013)	Michel Benoist [France]	The Michel Benoist and Robert Mulholland yearly European Spine Journal Review
000853 (2013)	Andra Balanescu [Roumanie] ; Piotr Wiland [Pologne]	Maximizing early treatment with biologics in patients with rheumatoid arthritis: the ultimate breakthrough in joints preservation
000873 (2012)	Eugenia K. Page [États-Unis] ; Wasim A. Dar [États-Unis] ; Stuart J. Knechtle [États-Unis]	Biologics in organ transplantation
000925 (2012)	P. A. Laires [Portugal] ; F. Exposto [Portugal] ; R. Mesquita [Portugal] ; A. P. Martins [Portugal] ; L. Cunha-Miranda [Portugal] ; J. E. Fonseca [Portugal]	Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries
000A43 (2013)	M. Aringer [Allemagne] ; T. Dörner [Allemagne]	Biosimilars
000A47 (2009)	E. Wipfler-Frei Muth [Autriche, Niger] ; J. Loock ; F. Moosig ; C. Dejaco [Autriche] ; C. Duftner [Autriche] ; M. Schirmer [Autriche]	Aktuelle Therapieansätze bei Riesenzellarteriitis
000A51 (2013)	Christian Gissel [Allemagne] ; Holger Repp [Allemagne]	Cost per responder of TNF-α therapies in Germany
000B21 (2013)	M. Lahiri [Royaume-Uni, Singapour] ; C. Morgan [Royaume-Uni] ; R. N. Luben ; D. K. Bunn [Royaume-Uni] ; M. Lunt [Royaume-Uni] ; S. M. Verstappen [Royaume-Uni] ; D. P. Symmons [Royaume-Uni] ; K.-T. Khaw ; N. J. Wareham ; I. N. Bruce [Royaume-Uni]	OP0046 A risk score to identify individuals at higher risk of inflammatory polyarthritis: Results from the european prospective investigation of cancer (norfolk) and the norfolk arthritis register (the EPIC-2-NOAR study)
000F77 (2013)	E. Koumakis [France] ; J. Wipff [France] ; M. Matucci-Cerinic [Italie] ; G. Riemekasten [Allemagne] ; P. Airo ; D. Cusi [Italie] ; H. E. Wichmann [Allemagne] ; U. Müller-Ladner [Allemagne] ; P. Vlachoyiannopoulos [Grèce] ; G. Chiocchia [France] ; Y. Allanore [France]	THU0012 TGFβ receptor polymorphisms in systemic sclerosis related pulmonary arterial hypertension: Results from a multicenter eustar study of european caucasian patients

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i -k "european" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i  \
                -Sk "european" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    european
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021